NASDAQ:HBIO Harvard Bioscience (HBIO) Stock Price, News & Analysis $8.03 0.00 (0.00%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$8.06 +0.04 (+0.44%) As of 09/11/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Harvard Bioscience Stock (NASDAQ:HBIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Harvard Bioscience alerts:Sign Up Key Stats Today's Range$8.02▼$8.1850-Day Range$5.92▼$8.2052-Week Range$3.75▼$9.40Volume8,345 shsAverage Volume19,124 shsMarket Capitalization$36.54 millionP/E RatioN/ADividend YieldN/APrice Target$6.75Consensus RatingHold Company Overview Harvard Bioscience, Inc. develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics. Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools. The company serves its customers via direct sales and an extensive distributor network, with significant operations in North America, Europe and the Asia‐Pacific region. Founded in 1901 and headquartered in Holliston, Massachusetts, Harvard Bioscience has grown through organic innovation and strategic acquisitions to support the evolving needs of life science research. The company maintains manufacturing and R&D facilities in the United States and Europe and is managed by an experienced team of professionals with backgrounds in engineering, sales and scientific product development.AI Generated. May Contain Errors. Read More Harvard Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks27th Percentile Overall ScoreHBIO MarketRank™: Harvard Bioscience scored higher than 27% of companies evaluated by MarketBeat, and ranked 798th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.4 / 5Analyst RatingHold Consensus RatingHarvard Bioscience has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Downside RiskHarvard Bioscience has a consensus price target of $6.75, representing about 15.9% downside from its current price of $8.03.Amount of Analyst CoverageHarvard Bioscience has only been the subject of 2 research reports in the past 90 days.Read more about Harvard Bioscience's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Harvard Bioscience is -3.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Harvard Bioscience is -3.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHarvard Bioscience has a P/B Ratio of 2.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Harvard Bioscience's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.28% of the float of Harvard Bioscience has been sold short.Short Interest Ratio / Days to CoverHarvard Bioscience has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Harvard Bioscience has recently decreased by 17.50%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHarvard Bioscience does not currently pay a dividend.Dividend GrowthHarvard Bioscience does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment1.32 News SentimentHarvard Bioscience has a news sentiment score of 1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.89 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Harvard Bioscience this week, compared to 2 articles on an average week. Company Ownership1.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Harvard Bioscience insiders have not sold or bought any company stock.Percentage Held by Insiders17.03% of the stock of Harvard Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions80.87% of the stock of Harvard Bioscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Harvard Bioscience's insider trading history. Receive HBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harvard Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HBIO Stock News HeadlinesHarvard Bioscience (NASDAQ:HBIO) Share Price Passes Above 200-Day Moving Average - Time to Sell?September 11 at 2:22 AM | americanbankingnews.comHarvard Bioscience (NASDAQ:HBIO) Stock Crosses Above 200 Day Moving Average - Here's WhySeptember 3, 2026 | americanbankingnews.comGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet production stayed at 5.9 million ounces, unchanged from 2020. Newmont, Barrick and Agnico all face the same reserve shortage, pushing majors toward acquiring smaller producing miners. Recent deals show the pattern: Rupert Resources jumped 67 percent and G2 Goldfields jumped 79 percent the day their buyouts were announced. Analyst Garrett Goggin has identified four junior miners he believes are next on the shopping list. | Golden Portfolio (Ad)Harvard Bioscience (HBIO) Q2 2026 Earnings Call TranscriptAugust 18, 2026 | finance.yahoo.comHarvard Bioscience Inc (HBIO) (Q2 2026) Earnings Call Highlights: Revenue Surges 11% and ...August 12, 2026 | finance.yahoo.comHarvard Bioscience Announces Second Quarter 2026 Financial ResultsAugust 12, 2026 | markets.businessinsider.comHarvard Bioscience, Inc. (HBIO) Q2 FY2026 earnings call transcriptAugust 12, 2026 | finance.yahoo.comHarvard Bioscience targets 3% to 5% full-year 2026 revenue growth as CMT and China mix shifts gross margin to 57% to 59%August 12, 2026 | seekingalpha.comSee More Headlines HBIO Stock Analysis - Frequently Asked Questions How have HBIO shares performed this year? Harvard Bioscience's stock was trading at $6.6880 on January 1st, 2026. Since then, HBIO stock has increased by 20.1% and is now trading at $8.03. How were Harvard Bioscience's earnings last quarter? Harvard Bioscience, Inc. (NASDAQ:HBIO) posted its quarterly earnings data on Tuesday, August, 11th. The medical instruments supplier reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.07. The medical instruments supplier earned $22.73 million during the quarter, compared to analyst estimates of $21.45 million. Harvard Bioscience had a negative net margin of 11.86% and a negative trailing twelve-month return on equity of 33.13%. Read the conference call transcript. When did Harvard Bioscience's stock split? Shares of Harvard Bioscience reverse split on the morning of Monday, March 16th 2026.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, March 15th 2026. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Does Harvard Bioscience have any subsidiaries? The following companies are subsidiaries of Harvard Bioscience: Data Sciences International. Who are Harvard Bioscience's major shareholders? Harvard Bioscience's top institutional shareholders include Weber Capital Management LLC ADV (6.89%), Meros Investment Management LP (4.02%) and Citadel Advisors LLC (0.29%). Insiders that own company stock include James W Green, John D Duke, William Snider and Stephen J Denelsky. View institutional ownership trends. How do I buy shares of Harvard Bioscience? Shares of HBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Harvard Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Harvard Bioscience investors own include YETI (YETI), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Alphabet (GOOG), Stag Industrial (STAG) and Tesla (TSLA). Company Calendar Last Earnings8/11/2026Today9/13/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 HBIO's financial health is in the Green zone, according to TradeSmith. HBIO has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:HBIO CIK1123494 Webwww.harvardbioscience.com Phone(508) 893-8999Fax508-429-5732Employees490Year Founded1901Price Target and Rating Average Price Target for Harvard Bioscience$6.75 High Price Target$7.50 Low Price Target$6.00 Potential Upside/Downside-15.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($2.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$56.70 million Net Margins-11.86% Pretax Margin-12.01% Return on Equity-33.13% Return on Assets-4.80% Debt Debt-to-Equity Ratio4.94 Current Ratio1.87 Quick Ratio0.98 Sales & Book Value Annual Sales$86.55 million Price / Sales0.42 Cash Flow$11.64 per share Price / Cash Flow0.69 Book Value$3.07 per share Price / Book2.62Miscellaneous Outstanding Shares4,550,000Free Float3,777,000Market Cap$36.54 million OptionableNo Data Beta1.53 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:HBIO) was last updated on 9/14/2026 by MarketBeat.com Staff. From Our PartnersThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredPrint this before your next tradeBill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97. It'...Profits Run | SponsoredA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredElon Musk to Trigger Next AI Wave on November 11th?Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredThis little-known gold fund distributes cash every FridayGold pays no dividends, no interest, no yield - it just sits there. Yet investors are reportedly collecting up...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harvard Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harvard Bioscience With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
